Login to Your Account

Gazyva tops Rituxan in PFS in first-line FL, but safety, OS data lag

By Jennifer Boggs
Managing Editor

Monday, December 5, 2016

SAN DIEGO – Gazyva, the drug considered a follow-on to blockbuster Rituxan, improved progression-free survival by 34 percent compared to Rituxan in patients with previously untreated follicular lymphoma, according to detailed data presented at ASH.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription